A recent report published by
Infinium Global Research on the metastatic breast cancer treatment market provides
an in-depth analysis of segments and sub-segments in the global as well as
regional metastatic breast cancer treatment market. The study also highlights
the impact of drivers, restraints, and macro indicators on the global and
regional metastatic breast cancer treatment market over the short term as well
as long term. The report is a comprehensive presentation of trends, forecast
and dollar values of the global metastatic breast cancer treatment market.
According to the report, the global metastatic breast cancer treatment market
is projected to grow at a CAGR of 9.4% over the forecast period of 2019-2025.
Cancer is a class of diseases
that cause cells in the body to change and proliferate out of control. Breast
cancer is the most primarily occurring cancer in women and the second most
common cancer worldwide. In 2018, there were approximately 2.09 million new
cases of breast cancer and 627000 deaths due to breast cancer. Metastatic
breast cancer also is referred to as stage IV or advanced breast cancer. It is
the most advanced stage of breast cancer. Metastatic breast cancer is breast
cancer that has spread further on the breast to other organs such as bones,
brain, liver or lungs. Despite the fact that metastatic breast cancer is viewed
as an incurable disease with a poor prognosis, many people pursue to live long and
productive lives with breast cancer in this stage. Cancer can be active and
then go into remission or there can be recurrence at other times. There is a
wide range of treatment alternatives for metastatic breast cancer, and new
medicines are being assessed daily. Treatments can be used alone, in sequence
or in combination.
The rising number of metastatic
breast cancer cases due to increasing consumption of tobacco and alcohol,
obesity, lack of physical activity, exposure to ionizing and ultraviolet radiation,
and urban air pollution is driving the metastatic breast cancer treatment
market globally. Initiatives taken by the government and NGOs to create
awareness regarding metastatic breast cancer and its increasing survival rate
due to technologically advanced treatments are boosting the market. Breast
cancer in men is rare, with less than 1% of breast cancer cases in the US. Men
at a greater extent than women are likely to be diagnosed with metastatic
breast cancer, as a result of unawareness and late diagnosis as screening
mammography is not suggested for men due to the rarity of the disease. Thus,
poor prognosis is one of the factors estimated to increase the overall
metastatic breast cancer treatment market. However, the high cost of the
treatment and several side effects associated with the treatments hinders the
growth of the market. Improving access to affordable care via health care
reform, increasing clinical trials and funding for research in treatments opens
further opportunities for the metastatic breast cancer treatment market.
The metastatic breast cancer
treatment market covers geographical regions such as North-America, Europe,
Asia-Pacific, and the Rest of the World. North-America accounts for the largest
revenue followed by Europe due to increased diagnosis of disease and enhanced
healthcare infrastructure. The Asia-pacific market is expected to increase
during the forecast period as a result of improving reimbursement policies,
large investments by market players in these regions as well as increased
funding for treatment in low and middle-income regions.
The report on the global metastatic
breast cancer treatment market covers segments such as treatment type, and end
user. On the basis of treatment type, the sub-markets include chemotherapy,
radiation therapy, biologic targeted therapy, breast surgery, and hormone
therapy. On the basis of end user, the sub-markets include hospitals, clinics,
and other users.
The report provides profiles of
the companies in the market such as F. Hoffmann-La Roche AG, Pfizer Inc.,
Novartis AG, Merck & Co., Inc., Eli Lilly and Company, GlaxoSmithKline Plc,
Johnson and Johnson, AstraZeneca Plc, Bayer AG, Sun Pharmaceutical Industries
Ltd, and Other companies.
The report provides deep insights
into the demand forecasts, market trends, and micro and macro indicators. In
addition, this report provides insights into the factors that are driving and
restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis
given in the report brings an insight into the investment areas that existing
or new market players can consider. The report provides insights into the
market using analytical tools such as Porter's five forces analysis and DRO
analysis of metastatic breast cancer treatment market. Moreover, the study
highlights current market trends and provides forecast from 2019-2025. We also
have highlighted future trends in the market that will affect the demand during
the forecast period. Moreover, the competitive analysis given in each regional
market brings an insight into the market share of the leading players.
Please Choose One of them.